O
KRRO icon

OrbiMed’s Korro Bio KRRO Stock Holding History

OrbiMed’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,400
Closed -$1.55M – 118
2025
Q3 		$1.55M Hold
32,400
– – 0.04% 100
2025
Q2 		$405K Hold
32,400
– – 0.01% 99
2025
Q1 		$564K Hold
32,400
– – 0.01% 105
2024
Q4 		$1.23M Buy
+32,400
New +$1.66M 0.03% 110

Other funds holding KRRO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

OrbiMed's KRRO Position: Q4 2025 in Review

OrbiMed sold out of Korro Bio (KRRO) in Q4 2025, closing a stake of 32,400 shares — an estimated $1.55M sold.

OrbiMed first reported a position in KRRO in Q4 2024 and held it in 4 quarters. The position peaked at $1.55M in Q3 2025. 83 funds tracked by Wall St. Rank hold KRRO as of Q4 2025.

  • OrbiMed reported no remaining Korro Bio position as of Q4 2025 after selling out during the quarter.
  • OrbiMed sold 32,400 Korro Bio shares in Q4 2025, an estimated $1.55M.
  • OrbiMed first reported a position in Korro Bio in Q4 2024 and held it in 4 quarters.
  • OrbiMed's Korro Bio position peaked at $1.55M in Q3 2025.
  • 83 funds tracked by Wall St. Rank held Korro Bio as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.